The stress response and the hypothalamic-pituitary-adrenal axis: from molecule to melancholia.

Organisms survive by maintaining equilibrium with their environment. The stress system is critical to this homeostasis. Glucocorticoids modulate the stress response at a molecular level by altering gene expression, transcription, and translation, among other pathways. The effect is the inhibition of the functions of inflammatory cells, predominantly mediated through inhibition of cytokines, such as IL-1, IL-6, and TNF-alpha. The central effectors of the stress response are the corticotrophin-releasing hormone (CRH) and locus coeruleus-norepinephrine (LC-NE)/sympathetic systems. The CRH system activates the stress response and is subject to modulation by cytokines, hormones, and neurotransmitters. Glucocorticoids also modulate the growth, reproductive and thyroid axes. Abnormalities of stress system activation have been shown in inflammatory diseases such as rheumatoid arthritis, as well as behavioural syndromes such as melancholic depression. These disorders are comparable to those seen in rats whose CRH system is genetically abnormal. Thus, the stress response is central to resistance to inflammatory and behavioural syndromes. In this review, we describe the response to stress at molecular, cellular, neuroendocrine and behavioural levels, and discuss the disease processes that result from a dysregulation of this response, as well as recent developments in their treatment.

[1]  D. Boumpas,et al.  Glucocorticoid Therapy for Immune-Mediated Diseases: Basic and Clinical Correlates , 1993, Annals of Internal Medicine.

[2]  G. Chrousos,et al.  Stress and reproduction: physiologic and pathophysiologic interactions between the stress and reproductive axes. , 1988, Advances in experimental medicine and biology.

[3]  J. Cidlowski,et al.  Regulation of apoptosis by steroid hormones , 1995, The Journal of Steroid Biochemistry and Molecular Biology.

[4]  R. Schleimer,et al.  Human endothelial cells prolong eosinophil survival. Regulation by cytokines and glucocorticoids. , 1989, Journal of immunology.

[5]  P. Deuster,et al.  Exercise and Circadian Rhythm-Induced Variations in Plasma Cortisol Differentially Regulate Interleukin-1β (IL-1β), IL-6, and Tumor Necrosis Factor-α (TNFα) Production in Humans: High Sensitivity of TNFα and Resistance of IL-6 , 1997 .

[6]  T. Kral,et al.  The immune-hypothalamic-pituitary-adrenal axis. , 1989, Endocrine reviews.

[7]  P. Barnes,et al.  Anti-inflammatory actions of glucocorticoids: molecular mechanisms. , 1998, Clinical science.

[8]  G. Chrousos,et al.  Corticotropin releasing hormone related behavioral and neuroendocrine responses to stress in Lewis and Fischer rats , 1992, Brain Research.

[9]  T. Insel,et al.  The dexamethasone suppression test in patients with primary obsessive-compulsive disorder , 1982, Psychiatry Research.

[10]  L. Phillips,et al.  Glucocorticoid effects on somatomedins and somatomedin inhibitors. , 1985, The Journal of clinical endocrinology and metabolism.

[11]  T. Bártfai,et al.  Cytokine Regulation of Neuronal Survival , 1992, Journal of neurochemistry.

[12]  G. Chrousos,et al.  The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. , 1995, The New England journal of medicine.

[13]  A. Waage,et al.  Glucocorticoids inhibit the production of IL 6 from monocytes, endothelial cells and fibroblasts , 1990, European journal of immunology.

[14]  P. Hindmarsh,et al.  Direct effects of corticotrophin‐releasing hormone on stimulated growth hormone secretion , 1998, Clinical endocrinology.

[15]  G. Chrousos,et al.  Impairment of adrenocortical function associated with increased plasma tumor necrosis factor-alpha and interleukin-6 concentrations in African trypanosomiasis. , 1994, Neuroimmunomodulation.

[16]  David Baltimore,et al.  NF-κB: Ten Years After , 1996, Cell.

[17]  P. Sawchenko,et al.  Type 1 interleukin‐1 receptor in the rat brain: Distribution, regulation, and relationship to sites of IL‐1–induced cellular activation , 1995, The Journal of comparative neurology.

[18]  S. Beck,et al.  Chronic corticosterone treatment maintains synaptic activity of CA1 hippocampal pyramidal cells: Acute high corticosterone administration increases action potential number , 1995, Synapse.

[19]  F. Goodwin,et al.  Clinical and biochemical manifestations of depression. Relation to the neurobiology of stress (2) , 1988, The New England journal of medicine.

[20]  A. Grossman,et al.  A comparison of the effects of human and ovine corticotropin-releasing hormone on the pituitary-adrenal axis. , 1995, The Journal of clinical endocrinology and metabolism.

[21]  E. Sternberg Emotions and disease: From balance of humors to balance of molecules , 1997, Nature Medicine.

[22]  H. Yarwood,et al.  Effect of glucocorticosteroids on microvascular permeability. , 1990, The American review of respiratory disease.

[23]  S. Akira,et al.  Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF) , 1990, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[24]  P. Landfield,et al.  Modulation of brain aging correlates by long-term alterations of adrenal steroids and neurally-active peptides. , 1987, Progress in brain research.

[25]  J. Cohen,et al.  Programmed cell death in the immune system. , 1991, Advances in immunology.

[26]  S. Lamberts,et al.  Corticotropin-releasing factor (ovine) and vasopressin exert a synergistic effect on adrenocorticotropin release in man. , 1984, The Journal of clinical endocrinology and metabolism.

[27]  H. Imura,et al.  Expression of adrenocorticotropin-releasing hormone precursor gene in placenta and other nonhypothalamic tissues in man. , 1988, Molecular endocrinology.

[28]  D. Koutras Disturbances of Menstruation in Thyroid Disease , 1997, Annals of the New York Academy of Sciences.

[29]  E. Remmers,et al.  Corticotropin-releasing hormone in synovial fluids and tissues of patients with rheumatoid arthritis and osteoarthritis. , 1993, Journal of immunology.

[30]  G. Chrousos,et al.  Elevated cerebrospinal fluid levels of immunoreactive corticotropin-releasing hormone in anorexia nervosa: relation to state of nutrition, adrenal function, and intensity of depression. , 1987, The Journal of clinical endocrinology and metabolism.

[31]  J V Castell,et al.  Interleukin-6 and the acute phase response. , 1990, The Biochemical journal.

[32]  G. Chrousos,et al.  Autocrine or paracrine inflammatory actions of corticotropin-releasing hormone in vivo. , 1991, Science.

[33]  P. J. Larsen,et al.  Substance P Inhibits the Release of Anterior Pituitary Adrenocorticotrophin via a Central Mechanism Involving Corticotrophin‐Releasing Factor‐Containing Neurons in the Hypothalamic Paraventricular Nucleus , 1993, Journal of neuroendocrinology.

[34]  G. Chrousos,et al.  Basic and clinical studies with corticotropin-releasing hormone. Implications for a possible role in panic disorder. , 1988, The Psychiatric clinics of North America.

[35]  W. Graninger,et al.  Anterior pituitary function in patients with newly diagnosed rheumatoid arthritis. , 1996, British journal of rheumatology.

[36]  Z. Werb Biochemical actions of glucocorticoids on macrophages in culture. Specific inhibition of elastase, collagenase, and plasminogen activator secretion and effects on other metabolic functions , 1978, The Journal of experimental medicine.

[37]  J. Calabrese,et al.  Responses to corticotropin-releasing hormone in the hypercortisolism of depression and Cushing's disease. Pathophysiologic and diagnostic implications. , 1986, The New England journal of medicine.

[38]  M. Joëls,et al.  Brain corticosteroid receptor balance in health and disease. , 1998, Endocrine reviews.

[39]  K. Matsushima,et al.  Dexamethasone inhibits the induction of monocyte chemotactic-activating factor production by IL-1 or tumor necrosis factor. , 1991, Journal of immunology.

[40]  G. Chrousos,et al.  Mechanisms of serotonin receptor agonist-induced activation of the hypothalamic-pituitary-adrenal axis in the rat. , 1990, Endocrinology.

[41]  Y. Levo,et al.  MAST-CELL DEGRANULATION IN CROHN'S DISEASE , 1978, The Lancet.

[42]  U. Stenman,et al.  Tumor necrosis factor as a potent inhibitor of adrenocorticotropin-induced cortisol production and steroidogenic P450 enzyme gene expression in cultured human fetal adrenal cells. , 1991, Endocrinology.

[43]  S. Yen,et al.  Expression of genes encoding corticotropin-releasing factor (CRF), type 1 CRF receptor, and CRF-binding protein and localization of the gene products in the human ovary. , 1997, The Journal of clinical endocrinology and metabolism.

[44]  K. Umesono,et al.  The nuclear receptor superfamily: The second decade , 1995, Cell.

[45]  G. Chrousos,et al.  Mechanisms of Glucocorticoid‐Resistant Asthma a , 1998, Annals of the New York Academy of Sciences.

[46]  S. Akira,et al.  Biological and clinical aspects of interleukin 6. , 1990, Immunology today.

[47]  G. Chrousos,et al.  Interactions between the Hypothalamic-Pituitary-Adrenal Axis and the Female Reproductive System: Clinical Implications , 1998, Annals of Internal Medicine.

[48]  E. Unanue,et al.  Corticosteroids inhibit murine macrophage Ia expression and interleukin 1 production. , 1982, Journal of immunology.

[49]  G. Koob,et al.  Corticotropin releasing factor produces behavioural activation in rats , 1982, Nature.

[50]  R. Schleimer,et al.  Inhibition of basophil histamine release by anti-inflammatory steroids , 1981, Nature.

[51]  A. Herz,et al.  A two-step mechanism by which corticotropin-releasing hormone releases hypothalamic beta-endorphin: the role of vasopressin and G-proteins. , 1989, Endocrinology.

[52]  Lars Bäckman,et al.  INTERLEUKIN-2-RECEPTOR BLOCKADE WITH DACLIZUMAB TO PREVENT ACUTE REJECTION IN RENAL TRANSPLANTATION , 1998 .

[53]  L. de wit,et al.  Glucocorticoid up-regulation of high-affinity interleukin 6 receptors on human epithelial cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[54]  R. Schleimer,et al.  Glucocorticoids inhibit eosinophil responses to granulocyte-macrophage colony-stimulating factor. , 1991, Journal of immunology.

[55]  G. Chrousos,et al.  In vitro and in vivo effects of the triazolobenzodiazepine alprazolam on hypothalamic-pituitary-adrenal function: pharmacological and clinical implications. , 1990, The Journal of clinical endocrinology and metabolism.

[56]  R. Dluhy The growing spectrum of HIV-related endocrine abnormalities. , 1990, The Journal of clinical endocrinology and metabolism.

[57]  C. Qualls,et al.  Assessment of stimulated and spontaneous adrenocorticotropin secretory dynamics identifies distinct components of cortisol feedback inhibition in healthy humans. , 1996, The Journal of clinical endocrinology and metabolism.

[58]  S. Targan,et al.  A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease , 1997 .

[59]  H. Hechtman,et al.  Endothelial-secreted arachidonic acid metabolites modulate polymorphonuclear leukocyte chemotaxis and diapedesis in vitro , 1988 .

[60]  T. Kakigi,et al.  Elevated urinary free cortisol in patients with dementia , 1991, Neurobiology of Aging.

[61]  R. Flower,et al.  The role of lipocortin in corticosteroid actions. , 1990, The American review of respiratory disease.

[62]  B. Burguera,et al.  Acute administration of corticoids: a new and peculiar stimulus of growth hormone secretion in man. , 1990, The Journal of clinical endocrinology and metabolism.

[63]  S. Wessely,et al.  Low-dose hydrocortisone in chronic fatigue syndrome: a randomised crossover trial , 1999, The Lancet.

[64]  G. Chrousos,et al.  Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. , 1993, The Journal of clinical endocrinology and metabolism.

[65]  D. Gladman,et al.  Cortisol catabolism by lymphocytes of patients with systemic lupus erythematosus and rheumatoid arthritis. , 1990, The Journal of rheumatology.

[66]  G. Chrousos,et al.  A corticotropin-releasing hormone type I receptor antagonist delays parturition in sheep. , 1998, Endocrinology.

[67]  K. Bacon,et al.  Potent and selective inhibition of in vitro lymphocyte migration by cyclosporine and dexamethasone. , 1990, Immunopharmacology and immunotoxicology.

[68]  P. Rothwell,et al.  Cortisol response to corticotropin and survival in septic shock , 1991, The Lancet.

[69]  S. Lamberts,et al.  Cortisol receptor resistance: the variability of its clinical presentation and response to treatment. , 1992, The Journal of clinical endocrinology and metabolism.

[70]  G. Chrousos,et al.  Abnormal neuroendocrine immune communications in patients with rheumatoid arthritis , 1992, European journal of clinical investigation.

[71]  S. Lamberts,et al.  Differential adaptation of glucocorticoid sensitivity of peripheral blood mononuclear leukocytes in patients with sepsis or septic shock. , 1995, The Journal of clinical endocrinology and metabolism.

[72]  A. Baldwin,et al.  THE NF-κB AND IκB PROTEINS: New Discoveries and Insights , 1996 .

[73]  M. Karin,et al.  Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. , 1997, The New England journal of medicine.

[74]  G. Chrousos,et al.  Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids. , 1996, Endocrine reviews.

[75]  M. Moroni,et al.  Cortisol resistance in acquired immunodeficiency syndrome. , 1992, The Journal of clinical endocrinology and metabolism.

[76]  G. Chrousos,et al.  The Stress Response and the Regulation of Inflammatory Disease , 1992, Annals of Internal Medicine.

[77]  D. Papanicolaou,et al.  The Pathophysiologic Roles of Interleukin-6 in Human Disease , 1998, Annals of Internal Medicine.

[78]  M. Demitrack,et al.  Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome. , 1991, The Journal of clinical endocrinology and metabolism.

[79]  J. Born,et al.  Acute effects of recombinant human interleukin-6 on endocrine and central nervous sleep functions in healthy men. , 1998, The Journal of clinical endocrinology and metabolism.

[80]  S. Szefler,et al.  Steroid-resistant asthma. Cellular mechanisms contributing to inadequate response to glucocorticoid therapy. , 1994, The Journal of clinical investigation.

[81]  R. Ekman,et al.  Biosynthesis of corticotropin-releasing hormone in human T-lymphocytes , 1993, Journal of Neuroimmunology.

[82]  A. Dvorak,et al.  MAST-CELL DEGRANULATION IN CROHN'S DISEASE , 1978, The Lancet.

[83]  M. Atkins,et al.  Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2-associated side effects [see comments] , 1990 .

[84]  G. Chrousos,et al.  Increased plasma concentrations, hypothalamic content, and in vitro release of arginine vasopressin in inflammatory disease-prone, hypothalamic corticotropin-releasing hormone-deficient Lewis rats. , 1992, Endocrinology.

[85]  S. Kasper,et al.  Abnormal pituitary-adrenal responses to corticotropin-releasing hormone in patients with seasonal affective disorder: clinical and pathophysiological implications. , 1991, The Journal of clinical endocrinology and metabolism.

[86]  A. Baldwin,et al.  The NF-kappa B and I kappa B proteins: new discoveries and insights. , 1996, Annual review of immunology.

[87]  M. Merino,et al.  Presence of immunoreactive corticotropin releasing hormone in thyroid lesions. , 1994, The American journal of pathology.

[88]  G. Chrousos,et al.  Bone mineral density in women with depression. , 1996, The New England journal of medicine.

[89]  J. Kremer,et al.  A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. , 1999, The New England journal of medicine.

[90]  A polymorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivo. , 1998, The Journal of clinical endocrinology and metabolism.